Daisuke Yabe
About
Daisuke Yabe is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery.
According to data from OpenAlex, Daisuke Yabe has authored 224 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Endocrinology, Diabetes and Metabolism, 80 papers in Molecular Biology and 74 papers in Surgery. Recurrent topics in Daisuke Yabe's work include Diabetes Treatment and Management (112 papers), Diabetes Management and Research (56 papers) and Metabolism, Diabetes, and Cancer (55 papers). Daisuke Yabe is often cited by papers focused on Diabetes Treatment and Management (112 papers), Diabetes Management and Research (56 papers) and Metabolism, Diabetes, and Cancer (55 papers). Daisuke Yabe collaborates with scholars based in Japan, United States and Germany. Daisuke Yabe's co-authors include Yutaka Seino, Joseph L. Goldstein, Michael S. Brown, Mitsuo Fukushima, Peter J. Espenshade, Tong Yang, Michael E. Wright, Yi Gong, Ruedi Aebersold and Hitoshi Kuwata and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
In The Last Decade
Daisuke Yabe
209 papers receiving 7.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Daisuke Yabe Japan | 37 | 3.3k | 3.2k | 2.7k | 862 | 744 | 224 | 7.5k | ||
| Gunilla Olivecrona Sweden | 52 | 2.1k 0.6× | 3.3k 1.0× | 1.7k 0.6× | 1.5k 1.7× | 691 0.9× | 175 | 8.5k | ||
| Karin Bornfeldt United States | 53 | 5.2k 1.5× | 2.2k 0.7× | 1.8k 0.7× | 1.7k 1.9× | 684 0.9× | 151 | 11.1k | ||
| Paolo Parini Sweden | 42 | 2.7k 0.8× | 1.3k 0.4× | 2.7k 1.0× | 1.3k 1.5× | 526 0.7× | 135 | 7.5k | ||
| Kathrin Maedler Germany | 42 | 2.9k 0.9× | 2.3k 0.7× | 3.8k 1.4× | 1.1k 1.3× | 2.3k 3.1× | 98 | 7.6k | ||
| Robert J. Konrad United States | 47 | 2.2k 0.7× | 1.2k 0.4× | 2.4k 0.9× | 958 1.1× | 379 0.5× | 151 | 6.9k | ||
| Youfei Guan China | 60 | 4.4k 1.3× | 1.7k 0.5× | 1.6k 0.6× | 1.7k 2.0× | 1.1k 1.5× | 226 | 10.3k | ||
| Clive R. Pullinger United States | 40 | 1.7k 0.5× | 1.5k 0.5× | 2.2k 0.8× | 567 0.7× | 561 0.8× | 122 | 6.0k | ||
| Raghavendra G. Mirmira United States | 47 | 3.1k 0.9× | 1.7k 0.5× | 3.9k 1.4× | 709 0.8× | 2.6k 3.4× | 185 | 6.8k | ||
| Yasushi Tanaka Japan | 44 | 2.9k 0.9× | 2.0k 0.6× | 981 0.4× | 1.4k 1.6× | 884 1.2× | 289 | 7.8k | ||
| Åke Sjöholm Sweden | 38 | 2.4k 0.7× | 2.2k 0.7× | 1.8k 0.7× | 908 1.1× | 563 0.8× | 158 | 6.0k |
Countries citing papers authored by Daisuke Yabe
Since
Specialization
Citations
This map shows the geographic impact of Daisuke Yabe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daisuke Yabe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daisuke Yabe more than expected).
Fields of papers citing papers by Daisuke Yabe
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Daisuke Yabe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daisuke Yabe. The network helps show where Daisuke Yabe may publish in the future.
Co-authorship network of co-authors of Daisuke Yabe
This figure shows the co-authorship network connecting the top 25 collaborators of Daisuke Yabe. A scholar is included among the top collaborators of Daisuke Yabe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daisuke Yabe. Daisuke Yabe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Okamoto, Kentaro, Masakatsu Sone, Daisuke Taura, et al.. (2025). The Significance of High Expression of Circulating miR-222-3p in Patients With Unilateral Primary Aldosteronism. The Journal of Clinical Endocrinology & Metabolism. 111(2). e420–e430.
2.
Ushiroda, Chihiro, et al.. (2025). Chrebp Deletion and Mild Protein Restriction Additively Decrease Muscle and Bone Mass and Function. Nutrients. 17(3). 488–488.
3.
Yamauchi, Ichiro & Daisuke Yabe. (2025). Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors. European Thyroid Journal. 14(1).
4.
Yabe, Daisuke, et al.. (2024). Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan. Diabetes Therapy. 15(3). 705–723.
5.
Murakami, Takaaki, Ikuko Hanaoka, Hiroyuki Fujimoto, et al.. (2024). [<sup>18</sup>F]FB(ePEG12)12-exendin-4 noninvasive imaging of insulinoma negative for insulin immunostaining on specimen from endoscopic ultrasonography-guided fine needle aspiration: a case report with review of literature. Endocrine Journal. 71(9). 925–933.
6.
Iizuka, Katsumi, Chihiro Ushiroda, Yusuke Seino, et al.. (2024). A Study on the Compatibility of a Food-Recording Application with Questionnaire-Based Methods in Healthy Japanese Individuals. Nutrients. 16(11). 1742–1742.
7.
Nakano, Eriko, Kosuke Mukai, Atsunori Fukuhara, et al.. (2024). Primary aldosteronism patients with previous cardiovascular and cerebrovascular events have high aldosterone responsiveness to ACTH stimulation. Endocrine Journal. 71(5). 489–497.
8.
Seino, Yusuke, Masashi Nakatani, Keisuke Hitachi, et al.. (2023). Blockade of glucagon increases muscle mass and alters fiber type composition in mice deficient in proglucagon‐derived peptides. Journal of Diabetes Investigation. 14(9). 1045–1055.
9.
Kato, Takehiro, Yuichi Hayashi, Hironori Fujii, et al.. (2023). Effectiveness of countermeasure for polypharmacy by multidisciplinary team review in patients with diabetes mellitus. Journal of Diabetes Investigation. 14(10). 1202–1208.
10.
Ji, Linong, Yingying Luo, Yong Mong Bee, et al.. (2023). Use of basal insulin in the management of adults with type 2 diabetes: An Asia‐Pacific evidence‐based clinical practice guideline. Journal of Diabetes. 15(6). 474–487.
11.
Takahashi, Yuya, Hiroki Fujita, Yusuke Seino, et al.. (2023). Gastric inhibitory polypeptide receptor antagonism suppresses intramuscular adipose tissue accumulation and ameliorates sarcopenia. Journal of Cachexia Sarcopenia and Muscle. 14(6). 2703–2718.
12.
Yabe, Daisuke, et al.. (2023). Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial ( EMPA‐ELDERLY ). Diabetes Obesity and Metabolism. 25(12). 3538–3548.
13.
Luo, Yingying, Jun Xia, Yaping Chang, et al.. (2023). Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta‐analysis. Journal of Diabetes. 15(5). 419–435.
14.
Fujii, Makoto, Yuko Ohno, Kayo Godai, et al.. (2023). Effect of the Diabetic Nephropathy Aggravation Prevention Program on medical visit behavior in individuals under the municipal national health insurance. Journal of Diabetes Investigation. 14(6). 782–791.
15.
Bouchi, Ryotaro, Tatsuya Kondo, Yasuharu Ohta, et al.. (2022). A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes. Journal of Diabetes Investigation. 14(1). 151–164.
16.
Haraguchi, Takuya, Hitoshi Kuwata, Yusuke Seino, et al.. (2022). Association of dipeptidyl peptidase‐4 inhibitor use and risk of pancreatic cancer in individuals with diabetes in Japan. Journal of Diabetes Investigation. 14(1). 67–74.
17.
Matsuhisa, Munehide, et al.. (2022). Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study. Diabetes Therapy. 14(1). 219–236.
18.
Yabe, Daisuke, et al.. (2021). Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. BMJ Open. 11(4). e045844–e045844.
19.
Yabe, Daisuke, Atsutaka Yasui, Linong Ji, et al.. (2018). Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials. Journal of Diabetes Investigation. 10(2). 418–428.
20.
Seino, Yutaka, et al.. (2017). Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study. Journal of Diabetes Investigation. 9(2). 332–340.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gunilla Olivecrona Breakdown of academic impact, for papers by Karin Bornfeldt Breakdown of academic impact, for papers by Paolo Parini Breakdown of academic impact, for papers by Kathrin Maedler Breakdown of academic impact, for papers by Robert J. Konrad Breakdown of academic impact, for papers by Youfei Guan Breakdown of academic impact, for papers by Clive R. Pullinger Breakdown of academic impact, for papers by Raghavendra G. Mirmira Breakdown of academic impact, for papers by Yasushi Tanaka Breakdown of academic impact, for papers by Åke Sjöholm